Atara Biotherapeutics (ATRA)
Market Price (3/28/2026): $4.67 | Market Cap: $63.6 MilSector: Health Care | Industry: Biotechnology
Atara Biotherapeutics (ATRA)
Market Price (3/28/2026): $4.67Market Cap: $63.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 52%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 48% | Weak multi-year price returns2Y Excs Rtn is -95%, 3Y Excs Rtn is -155% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -6.3%, Rev Chg QQuarterly Revenue Change % is -95% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 30% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -42%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -42% | |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -60% | High stock price volatilityVol 12M is 110% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Key risksATRA key risks include [1] a critically short financial runway creating substantial doubt about its ability to continue as a going concern, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 52%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 48% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 30% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -60% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -95%, 3Y Excs Rtn is -155% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -6.3%, Rev Chg QQuarterly Revenue Change % is -95% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -42%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -42% |
| High stock price volatilityVol 12M is 110% |
| Key risksATRA key risks include [1] a critically short financial runway creating substantial doubt about its ability to continue as a going concern, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Atara Biotherapeutics (ATRA) stock has lost about 70% since 11/30/2025 because of the following key factors:
1. Unexpected FDA Rejection of Key Drug Candidate Tabelecleucel (Ebvallo).
The primary driver of the stock's decline was the U.S. Food and Drug Administration's (FDA) issuance of a second Complete Response Letter (CRL) for Atara's lead drug candidate, tabelecleucel (Ebvallo), on January 9, 2026, announced on January 12, 2026. This rejection was particularly impactful because the FDA unexpectedly shifted its concerns from manufacturing issues, which had been previously resolved, to the adequacy of the single-arm ALLELE clinical trial design itself, stating it was no longer considered sufficient to provide evidence of effectiveness for accelerated approval. This decision contradicted the FDA's prior guidance and led to a significant stock plummet of approximately 57% on January 12, 2026, and resulted in the wipeout of more than two-thirds of the company's market capitalization within two trading days.
2. Loss of Critical Milestone Payment.
The FDA's rejection of tabelecleucel resulted in the forfeiture of a crucial $40 million milestone payment from Atara's partner, Pierre Fabre Laboratories, which was contingent upon FDA approval. This non-receipt of funds further exacerbated Atara's already challenged financial situation.
Show more
1. Unexpected FDA Rejection of Key Drug Candidate Tabelecleucel (Ebvallo).
The primary driver of the stock's decline was the U.S. Food and Drug Administration's (FDA) issuance of a second Complete Response Letter (CRL) for Atara's lead drug candidate, tabelecleucel (Ebvallo), on January 9, 2026, announced on January 12, 2026. This rejection was particularly impactful because the FDA unexpectedly shifted its concerns from manufacturing issues, which had been previously resolved, to the adequacy of the single-arm ALLELE clinical trial design itself, stating it was no longer considered sufficient to provide evidence of effectiveness for accelerated approval. This decision contradicted the FDA's prior guidance and led to a significant stock plummet of approximately 57% on January 12, 2026, and resulted in the wipeout of more than two-thirds of the company's market capitalization within two trading days.
2. Loss of Critical Milestone Payment.
The FDA's rejection of tabelecleucel resulted in the forfeiture of a crucial $40 million milestone payment from Atara's partner, Pierre Fabre Laboratories, which was contingent upon FDA approval. This non-receipt of funds further exacerbated Atara's already challenged financial situation.
Show more
Stock Movement Drivers
Fundamental Drivers
The -69.6% change in ATRA stock from 11/30/2025 to 3/27/2026 was primarily driven by a -78.1% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.10 | 4.59 | -69.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 152 | 121 | -20.5% |
| Net Income Margin (%) | 15.4% | 27.1% | 75.7% |
| P/E Multiple | 8.8 | 1.9 | -78.1% |
| Shares Outstanding (Mil) | 14 | 14 | -0.4% |
| Cumulative Contribution | -69.6% |
Market Drivers
11/30/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ATRA | -69.6% | |
| Market (SPY) | -5.3% | 8.8% |
| Sector (XLV) | -8.7% | 6.4% |
Fundamental Drivers
The -61.9% change in ATRA stock from 8/31/2025 to 3/27/2026 was primarily driven by a -92.5% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.05 | 4.59 | -61.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 189 | 121 | -36.0% |
| Net Income Margin (%) | 3.1% | 27.1% | 781.2% |
| P/E Multiple | 25.4 | 1.9 | -92.5% |
| Shares Outstanding (Mil) | 12 | 14 | -10.5% |
| Cumulative Contribution | -61.9% |
Market Drivers
8/31/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ATRA | -61.9% | |
| Market (SPY) | 0.6% | 14.9% |
| Sector (XLV) | 5.2% | 12.7% |
Fundamental Drivers
The -33.6% change in ATRA stock from 2/28/2025 to 3/27/2026 was primarily driven by a -45.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.91 | 4.59 | -33.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 100 | 121 | 20.2% |
| P/S Multiple | 0.5 | 0.5 | 0.8% |
| Shares Outstanding (Mil) | 7 | 14 | -45.2% |
| Cumulative Contribution | -33.6% |
Market Drivers
2/28/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ATRA | -33.6% | |
| Market (SPY) | 9.8% | 20.1% |
| Sector (XLV) | -2.1% | 15.3% |
Fundamental Drivers
The -95.5% change in ATRA stock from 2/28/2023 to 3/27/2026 was primarily driven by a -92.1% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 101.25 | 4.59 | -95.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 64 | 121 | 90.0% |
| P/S Multiple | 6.6 | 0.5 | -92.1% |
| Shares Outstanding (Mil) | 4 | 14 | -69.7% |
| Cumulative Contribution | -95.5% |
Market Drivers
2/28/2023 to 3/27/2026| Return | Correlation | |
|---|---|---|
| ATRA | -95.5% | |
| Market (SPY) | 69.4% | 21.1% |
| Sector (XLV) | 18.4% | 17.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ATRA Return | -20% | -79% | -84% | 4% | 36% | -74% | -99% |
| Peers Return | -14% | -65% | -11% | -55% | -1% | 30% | -84% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| ATRA Win Rate | 33% | 25% | 33% | 58% | 58% | 33% | |
| Peers Win Rate | 37% | 32% | 40% | 35% | 43% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| ATRA Max Drawdown | -39% | -82% | -93% | -47% | -60% | -77% | |
| Peers Max Drawdown | -45% | -67% | -43% | -58% | -41% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ALLO, CRSP, FATE, NTLA, EDIT. See ATRA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | ATRA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.9% | -25.4% |
| % Gain to Breakeven | 8916.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -68.0% | -33.9% |
| % Gain to Breakeven | 212.5% | 51.3% |
| Time to Breakeven | 240 days | 148 days |
| 2018 Correction | ||
| % Loss | -78.8% | -19.8% |
| % Gain to Breakeven | 372.5% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to ALLO, CRSP, FATE, NTLA, EDIT
In The Past
Atara Biotherapeutics's stock fell -98.9% during the 2022 Inflation Shock from a high on 2/8/2021. A -98.9% loss requires a 8916.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Atara Biotherapeutics (ATRA)
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
AI Analysis | Feedback
- The 'off-the-shelf' version of CAR T cell therapy pioneers like Gilead Sciences or Novartis.
- A Moderna or BioNTech, but for T-cell based cancer and autoimmune treatments.
AI Analysis | Feedback
- Tabelecleucel: A T-cell immunotherapy in Phase 3 clinical trials for Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease and other hematologic and solid tumors.
- ATA2271 and ATA3271: Next-generation CAR T immunotherapies being developed for mesothelin-expressing hematologic malignancies and solid tumors.
- ATA2431 and ATA3219: Next-generation CAR T immunotherapies targeting B-cell malignancies.
- ATA188: A T-cell immunotherapy in development for the treatment of multiple sclerosis.
- ATA368: A program focused on treatments for human papillomavirus (HPV) associated cancers.
AI Analysis | Feedback
Atara Biotherapeutics (ATRA) is a clinical-stage biotechnology company focused on developing T-cell immunotherapies. As such, the company does not currently have commercially available products or major customers in the traditional sense of selling treatments to other companies (e.g., hospitals, pharmacies) or directly to individuals. Its business model at this stage primarily involves research and development, conducting clinical trials, and forming strategic collaborations for the development of its pipeline products. Therefore, there are no major customers to list at this time.AI Analysis | Feedback
null
AI Analysis | Feedback
Cokey Nguyen, Ph.D. President and Chief Executive Officer
Dr. Cokey Nguyen was appointed President and Chief Executive Officer and named to the Board of Directors in September 2024. He is a recognized leader in the fields of cell therapy and oncology, possessing significant experience in the research and development of cell therapies, as well as oncology drug discovery and development within the biotech industry. Dr. Nguyen joined Atara in May 2021 as Chief Scientific Officer, where he focused on leading the development of next-generation allogeneic cell therapies for cancer and autoimmune diseases. Prior to his tenure at Atara, he served as Vice President, Innovation, Research and Development at Fate Therapeutics, where he was responsible for directing discovery and innovation efforts and spearheading corporate collaboration programs with ONO Pharma. Before that, Dr. Nguyen led the targeted immunotherapy group within the Oncology Research & Development team at Pfizer, successfully advancing bispecific antibodies for solid tumors and hematological malignancies into clinical trials.
Yanina Grant-Huerta Chief Accounting Officer & Principal Accounting Officer
Yanina Grant-Huerta was appointed as Chief Accounting Officer and principal accounting officer, effective March 31, 2025. She has been with Atara Biotherapeutics since 2020, having previously served as the Vice President of Financial Planning and Analysis.
K. Amar Murugan EVP and Chief Legal Officer
K. Amar Murugan has served as Executive Vice President and Chief Legal Officer at Atara Biotherapeutics since 2023.
Jim Sesic Senior Vice President of Regulatory Affairs
Jim Sesic is the Senior Vice President of Regulatory Affairs at Atara Biotherapeutics.
Alex Chapman Vice President of Corporate Communications & Investor Relations
Alex Chapman serves as the Vice President of Corporate Communications & Investor Relations for Atara Biotherapeutics.
AI Analysis | Feedback
Key Risks for Atara Biotherapeutics (ATRA)
- Clinical Trial Outcomes and Regulatory Approval: As a clinical-stage biopharmaceutical company, Atara Biotherapeutics' success is heavily dependent on the successful completion of clinical trials for its product candidates, especially tabelecleucel, which is in Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors. The failure of any of its product candidates to demonstrate safety and efficacy in clinical trials, or the inability to obtain necessary regulatory approvals, would significantly jeopardize the company's ability to generate revenue and could lead to a substantial decline in its business prospects and stock value.
- Intense Competition and Rapid Technological Advancements: Atara operates in the highly competitive and rapidly evolving field of T-cell immunotherapy and oncology. The company is developing next-generation CAR T immunotherapies and other T-cell therapies. Competitors, including larger pharmaceutical companies and other biotechnology firms, may develop or commercialize products that are more effective, safer, less expensive, or otherwise superior to Atara's product candidates. Rapid technological advancements could also render Atara's current technologies or product candidates obsolete or non-competitive before they achieve commercial success.
AI Analysis | Feedback
null
AI Analysis | Feedback
```htmlAtara Biotherapeutics (symbol: ATRA) operates in several significant addressable markets for its main product candidates:
- Tabelecleucel (tab-cel) for Epstein-Barr virus (EBV)-driven Post-Transplant Lymphoproliferative Disease (PTLD): The global Epstein-Barr Virus (EBV) market size was valued at approximately USD 1.5 billion in 2024 and is projected to reach USD 2.67 billion by 2035. North America's EBV market size was USD 0.52 billion in 2024. EBV-associated cancers, including PTLD, accounted for 55.4% of the EBV market in 2024. In the U.S., EBV+ PTLD occurs in fewer than 1,000 cases per year.
- Tabelecleucel for Nasopharyngeal Carcinoma (NPC): The global nasopharyngeal cancer market was valued at approximately USD 1.186.21 million in 2024 and is expected to increase to USD 2032.95 million by 2031. Another estimate places the global market at USD 1.62 billion in 2025, projected to reach USD 2.74 billion by 2032. North America held the largest share in the nasopharyngeal carcinoma treatment market in 2024, with a valuation of USD 1.064 billion. The Asia-Pacific region is projected to be the fastest-growing market and held the largest revenue share of 41.20% in 2025.
-
Next-generation CAR T Immunotherapies (including for Mesothelin and B-cell Malignancies):
- Overall CAR T-cell therapy market: The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033. Another report estimates the global market at USD 5.206.15 million in 2025, expanding to approximately USD 23,247.29 million by 2034. North America dominated the global CAR T-cell therapy market, holding a 61.14% revenue share in 2025.
- B-cell Malignancies (B-cell Lymphoma): The global B-cell lymphoma market was valued at USD 5.08 billion in 2024 and is projected to reach USD 10 billion by 2034. The global B-cell Non-Hodgkin Lymphoma market was valued at USD 8.2 billion in 2024 and is projected to generate USD 22.3 billion by the end of 2033. The U.S. B-cell lymphoma market size was USD 1.39 billion in 2024 and is projected to be around USD 2.78 billion by 2034. North America held the largest share of 39% in the B-cell lymphoma market in 2024.
- Mesothelin-targeted Therapies: Mesothelin is identified as an emerging target for CAR T-cell treatments for solid tumors. While mentioned as a segment within the broader CAR T-cell therapy market, a specific addressable market size for mesothelin-targeted therapies was not found.
- ATA188 for Multiple Sclerosis: The global multiple sclerosis therapeutic market size was estimated at USD 27.39 billion in 2024 and is projected to reach USD 38.62 billion by 2030. North America leads this market, holding a 38.28% share in 2024, with the U.S. dominating the North American market. The U.S. multiple sclerosis market alone was USD 11 billion in 2024.
- ATA368 program for Human Papillomavirus (HPV) associated cancers: The global HPV associated disorders market size was estimated at USD 18.5 billion in 2024 and is projected to reach USD 28.5 billion by 2033. North America held the largest share of 37.55% of the global HPV associated disorders market in 2024. The U.S. market for HPV associated disorders was valued at USD 6.30 billion in 2024 and is expected to reach USD 6.55 billion in 2025.
AI Analysis | Feedback
Atara Biotherapeutics (ATRA) anticipates several key drivers for future revenue growth over the next two to three years, primarily centered around its lead T-cell immunotherapy programs.
-
Potential U.S. Regulatory Approval and Commercialization of EBVALLO (tabelecleucel): The most significant near-term revenue driver is the potential U.S. Food and Drug Administration (FDA) approval of tabelecleucel (EBVALLO) for Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease (PTLD). Although the FDA issued a Complete Response Letter (CRL) in January 2026, Atara and its partner, Pierre Fabre, are actively addressing the concerns and have scheduled a Type A meeting with the FDA to discuss a resubmission. A successful approval would trigger milestone payments from Pierre Fabre and generate royalties for Atara from U.S. sales.
-
Expansion of EBVALLO Sales and Royalties in Licensed Territories: EBVALLO is already approved by the European Commission (EC) and commercialized in Europe, the Middle East, Africa, and other select emerging markets by Pierre Fabre. Continued market penetration and sales growth in these regions will translate into ongoing tiered royalty revenue for Atara, contributing to future top-line growth.
-
Clinical Advancement and Potential Partnering of ATA3219: Atara's next-generation CAR T program, ATA3219, is a lead candidate targeting B-cell malignancies, including non-Hodgkin's lymphoma (NHL), and autoimmune diseases such as lupus nephritis. Initial data for the NHL trial was expected in the fourth quarter of 2024, and initial data for lupus nephritis is anticipated in the first half of 2025. Positive clinical trial results and progression through development stages could significantly enhance the program's value, potentially leading to new collaboration agreements, upfront payments, and future milestone payments as development advances.
AI Analysis | Feedback
Share Issuance
- In February 2026, Atara Biotherapeutics issued a warrant to HealthCare Royalty (HCRx) to purchase up to 400,000 shares of common stock at a nominal exercise price of $0.0001 per share. This issuance was part of an agreement to delay a $9.0 million milestone payment.
Inbound Investments
- Atara Biotherapeutics entered into a strategic collaboration with Pierre Fabre in 2021 to commercialize tabelecleucel (tab-cel®) in Europe, the Middle East, Africa, and other select emerging markets.
- The company is eligible to receive a $40 million milestone payment from Pierre Fabre Laboratories upon FDA approval of the tab-cel Biologics License Application (BLA).
- Atara received $31.0 million (net of certain transaction expenses) from HealthCare Royalty (HCRx) in exchange for the right to receive specific Ebvallo royalties and milestone payments from Pierre Fabre.
Capital Expenditures
- Total operating expenses for full-year 2025 were projected to decrease by at least 60% compared to 2024, a result of transitioning substantially all tab-cel activities and associated costs to Pierre Fabre Laboratories, along with implemented operational efficiencies.
- Research and development expenses saw a significant decline from $43.9 million in the third quarter of 2024 to $2.9 million in the third quarter of 2025. This reduction was primarily due to the winding down of allogeneic CAR-T programs and the transfer of tab-cel-related costs.
- As part of a strategic pivot in 2025, Atara underwent multiple workforce reductions, decreasing its headcount to approximately 15 by October, and implemented a 29% reduction in its workforce.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ATRA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.42 |
| Mkt Cap | 0.4 |
| Rev LTM | 24 |
| Op Inc LTM | -177 |
| FCF LTM | -158 |
| FCF 3Y Avg | -185 |
| CFO LTM | -157 |
| CFO 3Y Avg | -182 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -28.8% |
| Rev Chg 3Y Avg | 51.5% |
| Rev Chg Q | -26.4% |
| QoQ Delta Rev Chg LTM | -12.6% |
| Op Mgn LTM | -448.4% |
| Op Mgn 3Y Avg | -1,041.5% |
| QoQ Delta Op Mgn LTM | 16.1% |
| CFO/Rev LTM | -495.6% |
| CFO/Rev 3Y Avg | -769.8% |
| FCF/Rev LTM | -497.1% |
| FCF/Rev 3Y Avg | -780.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 13.2 |
| P/EBIT | -2.1 |
| P/E | -2.0 |
| P/CFO | -2.4 |
| Total Yield | -33.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -55.7% |
| D/E | 0.1 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -10.0% |
| 3M Rtn | 9.9% |
| 6M Rtn | -25.0% |
| 12M Rtn | 38.8% |
| 3Y Rtn | -67.1% |
| 1M Excs Rtn | -7.5% |
| 3M Excs Rtn | 16.5% |
| 6M Excs Rtn | -21.3% |
| 12M Excs Rtn | 29.0% |
| 3Y Excs Rtn | -129.8% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Business of developing therapeutics | 129 | 9 | 64 | 20 | |
| Total | 129 | 9 | 64 | 20 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Business of developing therapeutics | -85 | -276 | |||
| Total | -85 | -276 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Business of developing therapeutics | 588 | ||||
| Total | 588 |
Price Behavior
Price Behavior
| Market Price | $4.59 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 10/16/2014 | |
| Distance from 52W High | -74.6% | |
| 50 Days | 200 Days | |
| DMA Price | $5.06 | $10.81 |
| DMA Trend | down | down |
| Distance from DMA | -9.4% | -57.5% |
| 3M | 1YR | |
| Volatility | 173.2% | 110.5% |
| Downside Capture | 1.30 | 0.81 |
| Upside Capture | -547.89 | 53.21 |
| Correlation (SPY) | 7.6% | 18.0% |
ATRA Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.57 | 1.80 | 1.91 | 1.88 | 1.16 | 1.79 |
| Up Beta | 6.03 | 10.40 | 7.39 | 6.55 | 0.99 | 1.09 |
| Down Beta | 0.20 | 1.43 | 1.63 | 1.93 | 1.50 | 1.89 |
| Up Capture | 437% | -465% | -261% | -67% | 61% | 324% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 9 | 19 | 31 | 66 | 133 | 355 |
| Down Capture | 316% | 319% | 258% | 134% | 109% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 20 | 28 | 56 | 113 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATRA | |
|---|---|---|---|---|
| ATRA | -33.4% | 110.5% | 0.24 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 15.3% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 18.2% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 2.8% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 3.2% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 15.1% |
| Bitcoin (BTCUSD) | -21.0% | 44.0% | -0.41 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATRA | |
|---|---|---|---|---|
| ATRA | -59.1% | 113.7% | -0.13 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 22.7% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 28.5% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 5.7% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -0.2% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 25.2% |
| Bitcoin (BTCUSD) | 4.7% | 56.6% | 0.30 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ATRA | |
|---|---|---|---|---|
| ATRA | -36.6% | 95.6% | 0.04 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 28.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 32.0% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 4.2% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 6.6% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 23.0% |
| Bitcoin (BTCUSD) | 66.9% | 66.8% | 1.06 | 9.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/16/2026 | -10.9% | -17.5% | |
| 11/12/2025 | -0.7% | 7.2% | 43.3% |
| 7/14/2025 | -0.3% | 23.7% | 24.1% |
| 3/7/2025 | -10.7% | 5.1% | -17.0% |
| 11/12/2024 | 22.2% | -5.8% | -6.2% |
| 8/12/2024 | 3.2% | -7.5% | 6.9% |
| 3/28/2024 | -0.9% | 11.3% | -1.4% |
| 11/1/2023 | -2.3% | 3.1% | -48.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 7 |
| # Negative | 13 | 12 | 12 |
| Median Positive | 6.1% | 9.2% | 24.1% |
| Median Negative | -5.4% | -7.6% | -16.9% |
| Max Positive | 29.2% | 47.1% | 60.3% |
| Max Negative | -20.8% | -25.9% | -48.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/16/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/08/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/16/2026 | Prior: Q4 2025 Earnings Reported 1/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Cash Runway | 2,026 | ||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nguyen, Anhco | President and CEO | Direct | Sell | 11192025 | 13.19 | 2,915 | 38,437 | 856,750 | Form |
| 2 | Grant-Huerta, Yanina | Chief Accounting Officer | Direct | Sell | 11192025 | 13.19 | 1,804 | 23,788 | 441,134 | Form |
| 3 | Nguyen, Anhco | President and CEO | Direct | Sell | 8202025 | 11.62 | 2,958 | 34,360 | 788,602 | Form |
| 4 | Grant-Huerta, Yanina | Chief Accounting Officer | Direct | Sell | 8202025 | 11.61 | 1,809 | 21,009 | 409,479 | Form |
| 5 | Panacea, Innovation Ltd | See Footnotes | Buy | 8192025 | 12.19 | 55,000 | 670,422 | 17,126,248 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.